Antithrombins - Research News and Information

Thursday, January 08, 2009

Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial.

30 Oct 2008 BACKGROUND: The overall finding in the KyberSept trial of no treatment effect of high-dose antithrombin (AT) in severe sepsis was inconsistent for the primary outcome, 28-day mortality, possibly because of patient heterogeneity. No data have been ... Read more...

Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study.

27 Sep 2008 BACKGROUND: Whether hereditary protein S, protein C, or antithrombin deficiency is associated with arterial thromboembolism (ATE) and whether history of venous thromboembolism in these subjects predisposes them to subsequent ATE have yet to be ... Read more...

A comparison of the pharmacokinetics of antithrombin derived from human plasma and from transgenic goats and the prevention of sepsis in an animal model.

30 Aug 2008 Antithrombin (AT) is the principal inhibitor of thrombin and other serine proteases of the coagulation cascade. AT has previously been prepared from human plasma (hpAT), and a transgenic variant from goat milk (tgAT) is now available. Two ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Antithrombins'

These are the very latest articles for this heading:

• Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. 30 Oct 2008
• Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. 27 Sep 2008
• A comparison of the pharmacokinetics of antithrombin derived from human plasma and from transgenic goats and the prevention of sepsis in an animal model. 30 Aug 2008
• 3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function. 25 Aug 2008
• Possible association of venous thromboembolism and hyperthyroidism: 4 case reports and literature review. 20 Aug 2008
• Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. 11 Aug 2008
• Burn injuries: is antithrombin back on stage in critical care? 30 Jul 2008
• The efficacy of antithrombin administration in the acute phase of burn injury. 30 Jul 2008
• Advances in understanding pathogenic mechanisms of thrombophilic disorders. 29 Jun 2008
• Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. 29 Jun 2008
• Hyperhomocysteinemia, antithrombin consumption, and early venous graft closure in surgical coronary revascularization. 29 Jun 2008
• Heparin is procoagulant in the absence of antithrombin. 29 Jun 2008
• A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. 30 May 2008
• Treating heparin resistance with antithrombin or fresh frozen plasma. 30 May 2008
• The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. 30 May 2008
• [Cancer chemotherapy and anticoagulant prophylaxis] 30 May 2008
• Sulfated galactan is a catalyst of antithrombin-mediated inactivation of alpha-thrombin. 26 May 2008
• Bivalirudin during primary PCI in acute myocardial infarction. 20 May 2008
• Antithrombotic therapy to support primary PCI. 20 May 2008
• The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease. 18 May 2008

See a longer list of these articles.

Technical information about 'Antithrombins'

Definition: An endogenous family of proteins belonging to the serpin superfamily that neutralizes the action of thrombin. Six naturally occurring antithrombins have been identified and are designated by Roman numerals I to VI. Of these, Antithrombin I (see FIBRIN) and ANTITHROMBIN III appear to be of major importance.

Registry Number: 0

Descriptor UI: D000991

Alternative terms: Antithrombins;

Related Mesh Headings: Anticoagulants;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.872.060;

Online Note: use ANTITHROMBINS to search ANTITHROMBIN 1967-76 (as Prov 1966)

History Note: 76; was ANTITHROMBIN 1964-75 (Prov 1964-66)

Technical Notes: serpins & anticoagulants